{"entity":{"id":"frederick-locke","kind":"person","name":"Frederick L. Locke","aka":[],"tldr":"Led the ZUMA-7 trial that put CAR-T ahead of transplant in relapsed large B-cell lymphoma.","summary":"Frederick L. Locke is Chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center. He is known for leading the ZUMA-7 trial, which put CAR-T ahead of transplant in relapsed large B-cell lymphoma, and was principal investigator of ZUMA-1 and ZUMA-7 with axicabtagene ciloleucel. His selected paper reports axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. He is also a leader in CAR-T real-world outcomes and in managing the toxicity of cellular therapy.","asOf":"2026-09-08","links":[{"label":"Moffitt profile","url":"https://www.moffitt.org/providers/frederick-locke/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Locke%20FL%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":["car-t"],"targets":["cd19"],"drugs":["axicabtagene-ciloleucel"],"companies":[],"institutions":["moffitt"],"pathways":[],"terms":[],"trials":["zuma-7"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Department of Blood and Marrow Transplant and Cellular Immunotherapy","institutionId":"moffitt","specialisms":["CAR-T therapy","Lymphoma","Cellular therapy toxicity"],"profiles":[{"label":"Moffitt profile","url":"https://www.moffitt.org/providers/frederick-locke/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Locke%20FL%5BAuthor%5D"}],"papers":[{"title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2116133","doi":"10.1056/NEJMoa2116133"},{"title":"ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma","journal":"New England Journal of Medicine","year":2017,"url":"https://doi.org/10.1056/NEJMoa1707447","doi":"10.1056/NEJMoa1707447"}]},"route":"/people/frederick-locke/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"drug":[{"id":"axicabtagene-ciloleucel","kind":"drug","name":"Axicabtagene ciloleucel","route":"/drugs/axicabtagene-ciloleucel/"}],"institution":[{"id":"moffitt","kind":"institution","name":"Moffitt Cancer Center","route":"/institutions/moffitt/"}],"trial":[{"id":"zuma-7","kind":"trial","name":"ZUMA-7","route":"/trials/zuma-7/"}],"paper":[{"id":"paper-zuma-1-axi-cel-nejm-2017","kind":"paper","name":"ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma","route":"/key-papers/paper-zuma-1-axi-cel-nejm-2017/"},{"id":"paper-zuma-7-axi-cel-second-line-nejm-2022","kind":"paper","name":"ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early","route":"/key-papers/paper-zuma-7-axi-cel-second-line-nejm-2022/"}]}}